Portal de Periódicos da CAPES

Five-year results of a randomised comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary revascularisation

2015; European Association of Percutaneous Cardiovascular Interventions; Volume: 10; Issue: 11 Linguagem: Inglês

10.4244/eijy15m01_04

1969-6213

Thomas Pilgrim, Lorenz Räber, Andreas Limacher, Peter Wenaweser, Stéphane Cook, Jean‐Christophe Stauffer, Ali Garachemani, Aris Moschovitis, Bernhard Meier, Peter Jüni, Stephan Windecker,

Cerebrovascular and Carotid Artery Diseases

Aims: Stents with a passive coating of titanium-nitride-oxide (TiNO) have been compared with Endeavor ® zotarolimus-eluting stents (E-ZES) with regard to the primary endpoint of in-stent late lumen loss at six to eight months.The objective of the present analysis was to compare the long-term outcomes of TiNO stents with E-ZES up to five years of clinical follow-up.Methods and results: A total of 302 patients had been randomly allocated to treatment with TiNO or E-ZES.Up to five years of follow-up, major adverse cardiac events (MACE), the composite of cardiac death, myocardial infarction, or clinically indicated target vessel revascularisation (TLR), were observed in 27.6% of patients treated with TiNO stents and 25.3% of patients treated with E-ZES (RR 1.13, 95% CI: 0.72-1.75,p=0.60), with the majority of events related to clinically indicated TVR (TiNO 21.7% versus E-ZES 20.7%, RR 1.10, 95% CI: 0.67-1.81).There were no differences with respect to individual events including cardiac death, myocardial infarction or stent thrombosis between the two treatment arms up to five years of followup.A majority of patients remained free from angina throughout the entire study duration (TiNO 77.3% versus E-ZES 76.1%, p=0.92).Conclusions: Final five-year outcomes of the TIDE trial comparing TiNO stents with E-ZES revealed increased rates of MACE driven primarily by clinically indicated TVR.The TIDE trial is registered at ClinicalTrials.gov:NCT00492908.